ENDObesity® II Study: TransPyloric Shuttle® System for Weight Loss
Completed · Not applicable · Has a placebo group
Conditions studied: Obesity
In brief
The purpose of this clinical research trial is to study safety and effectiveness of the TransPyloric Shuttle System (TPSS) for weight reduction in patients who are considered medically obese.
Key facts
- Study ID
- NCT02518685
- Run by
- BaroNova, Inc.
- People needed
- 302
- Starts
- 2015-09-01
- Expected to finish
- 2018-03-01
- Last updated by the study team
- 2019-07-17
Who can join
Age: 22 and older, up to 60. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Male and female subjects between the ages of 22 to 60
- A BMI between 30.0 to 40.0 kg/m2, inclusive. Subjects with a BMI of 30.0 kg/m2 to 34.9 kg/m2 are required to have one or more obesity-related comorbidities
- History of obesity for at least 2 years, with history of failure of medically or commercially supervised weight loss program
- < 5% change in body weight for at least 3 months
- Negative pregnancy test, agree to be on birth control for the duration of participation
- Informed consent
- Willing and able to comply with study procedures
You may not qualify if…
- Pregnancy or nursing
- Hormonal or genetic cause for obesity
- Prior history of any GI surgery or endoscopic intervention
- Chronic use of medications likely to contribute to weight gain or prevent weight loss
- Gastric or duodenal ulcers
- Positive for H. pylori
- History of severe dyspepsia
- GI tract motility disorders
- History of inflammatory disease of GI tract, coeliac disease, pancreatitis, portal hypertension, cirrhosis, and/or varices
- Diabetes treated with insulin
- HbA1c >7.5%
- Uncontrolled thyroid and adrenal gland disease or uncontrolled hypertension
- History of certain cardiac events
- Localized or systemic infection
- Anemia
- History of asthma likely to require systemic steroid therapy
- Autoimmune connective tissue disorders or immunocompromised
- History of malignancy except non-melanoma skin cancer
- Continuous use of ulcerogenic medication
- On anticoagulation or antiplatelet therapy
- Use of weight-loss medication
- In other weight-loss program
- Unable to take proton pump inhibitor
- Abnormal laboratory values or EKG
- Inability to walk at least 0.8 kilometers per day
Where it is running
- HonorHealth Bariatric Center — Scottsdale, Arizona, United States
- University of California San Diego — San Diego, California, United States
- University of Miami — Miami, Florida, United States
- Washington University School of Medicine — St Louis, Missouri, United States
- Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire, United States
- Stony Brook Medicine — Stony Brook, New York, United States
- MidSouth Bariatrics — Memphis, Tennessee, United States
- Vanderbilt University Medical Center — Nashville, Tennessee, United States
- Baylor University Medical Center — Dallas, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.